Collaboration combines Novo Nordisk's scientific leadership in obesity and cardiometabolic diseases with Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop mul ...

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained attention in various research studies ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

Researchers observe how fluctuations in ovarian hormones shape the structure and function in the mouse hippocampus, with ...

In Biology 101, we learn that RNA is a single, ribbon-like strand of base pairs that is copied from our DNA and then read ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

New research by scientists at the University of Toronto and the Structural Genomics Consortium has deepened our understanding ...

A recent study published in Life Metabolism has uncovered a surprising new player in the body’s ability to regulate blood ...

BACKGROUND: Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism ...